Sunday, January 25, 2015

Our last 2 publisher picks: TSGL gained over 400% on Friday ended at the high of the day, our previous pick PPCH had gains of over 200% all day long! New pick coming Monday!

Many of our publisher picks rise 100%, 200% or more once they hit the front page of our blog. Get some, sit back and enjoy the ride! Recent big winners include BSTO, XCLL, HHSE, UAPC, AEMD, XTRN, RGMI, PPCH and TSGL which gained 400% last Friday.

With over 1 million visitors to our blog and thousands of visitors daily, Sierra World Equity Review will be giving MASSIVE MULTIPLE DAY targeted audience exposure to our latest publisher pick to be announced here on Monday, January 26th 2014 one hour before the close of the markets.

Follow Sierra on Twitter To Get Our Next Publisher Pick~~Follow Sierra on Twitter

About Sierra World Equity Review

Every day we present our publisher's pick where we profile a stock that our publisher has taken a position in, we believe that the stock is extremely undervalued with potential for significant percentage gains. We also issue short term daily buy or sell ratings with 5 day price targets for stocks in all industries across all markets. 

Sierra World Equity Review and it's publisher have not been compensated to promote any stock but do hold a long position in the stocks we feature. We are not affiliated with any executives, owners, brokers, promoters or analysts. The publisher of Sierra World Equity Review is not a registered investment adviser, before making a purchase or sale of any securities featured on this site, we strongly recommend consultation with a registered securities representative. Please remember to do your own due diligence in regards to any stocks that appear on our websites, please read our disclaimer and privacy policy below.

Thursday, January 22, 2015

Our Publisher Pick Is The Staffing Group (TSGL), Millions In Revenues With Net Revenues Up A WHOPPING 62%, Operating In 3 States, Only 35 Million O/S Most Owned By The Insiders And A ALLOTCBB Price Target Of 0.31 Cents, TSGL Might Just Be The Most Undervalued Stock We Have Ever Seen, Trading Now At Historic Lows!

****Our Latest Publisher Pick is The Staffing Group (TSGL) ****

Many of our publisher picks rise 100%, 200% or more once they hit the front page of our blog. Get some, sit back and enjoy the ride! Recent big winners include BSTO, XCLL, GRLT, HHSE, UAPC, AEMD, XTRN, RGMI and our previous pick PPCH which ran up over 200% and counting!

With over 1 million visitors to our blog and thousands of visitors daily, Sierra World Equity Review will be giving MASSIVE MULTIPLE DAY targeted audience exposure to our latest publisher pick The Staffing Group (TSGL), with millions in revenues and net revenues up a WHOPPING 62%, operating in 3 states, only 35 Million O/S most owned by the insiders and a price target of 0.31 cents, TSGL might just be the most undervalued stock we have ever seen, trading now at historic lows! 

 


Here is why our publisher has initiated a long position in The Staffing Group (TSGL):

The Staffing Group (TSGL) generates revenues through it's subsidiary EmployUS a highly successful staffing company formed in September 2010 to respond to the relief and recovery of the major oil spill in the Gulf of Mexico.  


EmployUS, has since expanded to provide services on most major construction, chemical, and maritime projects in the Southeast United States. From its single initial project three years ago, EmployUS has grown to ten offices in three stateswith sales exceeding $15,000,000, more than 150 customers and over 3,000 people employed as of September 30, 2014

For the most recent 3 month period ending September 2014 The Staffing Group (TSGL) generated over $5 Million in net revenues ($5,187,602 to be exact) 

For the 9 month period ending September 2014 The Staffing Group (TSGL) generated almost $17 Million in net revenues ($16,715,436 to be exact) up a WHOPPING 62% for the same time frame in 2013.

From it's most recent September 2014 10Q filing The Staffing Group (TSGL) has assets of over a million dollars ($1,907,245 million to be exact)


The Staffing Group (TSGL) has a great share structure with only 35,100,011 million O/S and a float of approximately 23 million. On the latest 10Q insiders are reported to hold over 90% of the O/S meaning that the share price here could move up very quickly!!

The Staffing Group (TSGL) is current on it's SEC reporting and has audited financials. (A very healthy sign!)

ALLOTCBB has a 0.31 cent SIX month price target for The Staffing Group (TSGL), this stock is so under the radar that the potential for huge percentage gains is possible especially considering the 52 week high hit 0.59 cents AND NOW with the company revenue growth up a WHOPPING 62% (9 month period September 2014 vs 2013) the stock looks ready to bounce back. NOW is the time to buy The Staffing Group (TSGL).


Follow Sierra on Twitter To Get Our Next Publisher Pick~~Follow Sierra on Twitter

About Sierra World Equity Review

Every day we present our publisher's pick where we profile a stock that our publisher has taken a position in, we believe that the stock is extremely undervalued with potential for significant percentage gains. We also issue short term daily buy or sell ratings with 5 day price targets for stocks in all industries across all markets. 

Sierra World Equity Review and it's publisher have not been compensated to promote The Staffing Group (TSGL) but do hold a long position in the stock. We are not affiliated with any executives, owners, brokers, promoters or analysts. The publisher of Sierra World Equity Review is not a registered investment adviser, before making a purchase or sale of any securities featured on this site, we strongly recommend consultation with a registered securities representative. Please remember to do your own due diligence in regards to any stocks that appear on our websites, please read our disclaimer and privacy policy below.

Tuesday, January 20, 2015

Thursday, January 22nd 2015 ~ Our Publisher Pick Is Propanc Health Group Corp. (PPCH), Currently Trading In The Sub-Penny Range Is The MOST UNDERVALUED Biotech Stock Across All Markets. It's Revolutionary Peer Reviewed Cancer Fighting Drug PRP Is Set For FDA Regulatory Process And With The Company Actively Soliciting Big Pharma In Marketing Efforts For Potential Licensing Suitors, NOW Is The Time To Buy Shares!

****Our Latest Publisher Pick is The Staffing Group (TSGL) ****

Many of our publisher picks rise 100%, 200% or more once they hit the front page of our blog. Get some, sit back and enjoy the ride! Recent big winners include BSTO, XCLL, GRLT, HHSE, UAPC, AEMD, XTRN, RGMI and our previous pick PPCH which ran up over 200% and counting!

With over 1 million visitors to our blog and thousands of visitors daily, Sierra World Equity Review will be giving MASSIVE MULTIPLE DAY targeted audience exposure to our latest publisher pick The Staffing Group (TSGL), with millions in revenues and net revenues up a WHOPPING 62%, operating in 3 states, only 35 Million O/S most owned by the insiders and a price target of 0.31 cents, TSGL might just be the most undervalued stock we have ever seen, trading now at historic lows! 

 

Here is why our publisher has initiated a long position in The Staffing Group (TSGL):

The Staffing Group (TSGL) generates revenues through it's subsidiary EmployUS a highly successful staffing company formed in September 2010 to respond to the relief and recovery of the major oil spill in the Gulf of Mexico.  


EmployUS, has since expanded to provide services on most major construction, chemical, and maritime projects in the Southeast United States. From its single initial project three years ago, EmployUS has grown to ten offices in three stateswith sales exceeding $15,000,000, more than 150 customers and over 3,000 people employed as of September 30, 2014

For the most recent 3 month period ending September 2014 The Staffing Group (TSGL) generated over $5 Million in net revenues ($5,187,602 to be exact) 

For the 9 month period ending September 2014 The Staffing Group (TSGL) generated almost $17 Million in net revenues ($16,715,436 to be exact) up a WHOPPING 62% for the same time frame in 2013.

From it's most recent September 2014 10Q filing The Staffing Group (TSGL) has assets of over a million dollars ($1,907,245 million to be exact)


The Staffing Group (TSGL) has a great share structure with only 35,100,011 million O/S and a float of approximately 23 million. On the latest 10Q insiders are reported to hold over 90% of the O/S meaning that the share price here could move up very quickly!!

The Staffing Group (TSGL) is current on it's SEC reporting and has audited financials. (A very healthy sign!)

ALLOTCBB has a 0.31 cent SIX month price target for The Staffing Group (TSGL), this stock is so under the radar that the potential for huge percentage gains is possible especially considering the 52 week high hit 0.59 cents AND NOW with the company revenue growth up a WHOPPING 62% (9 month period September 2014 vs 2013) the stock looks ready to bounce back. NOW is the time to buy The Staffing Group (TSGL).


Follow Sierra on Twitter To Get Our Next Publisher Pick~~Follow Sierra on Twitter

About Sierra World Equity Review

Every day we present our publisher's pick where we profile a stock that our publisher has taken a position in, we believe that the stock is extremely undervalued with potential for significant percentage gains. We also issue short term daily buy or sell ratings with 5 day price targets for stocks in all industries across all markets. 

Sierra World Equity Review and it's publisher have not been compensated to promote The Staffing Group (TSGL) but do hold a long position in the stock. We are not affiliated with any executives, owners, brokers, promoters or analysts. The publisher of Sierra World Equity Review is not a registered investment adviser, before making a purchase or sale of any securities featured on this site, we strongly recommend consultation with a registered securities representative. Please remember to do your own due diligence in regards to any stocks that appear on our websites, please read our disclaimer and privacy policy below.

Idera Pharmaceuticals, Inc. (IDRA) SELL ~ 5 Day Price Target: $3.90 Issued 01/20/2015 By Sierra Equity

Idera Pharmaceuticals, Inc. (IDRA) SELL ~ 5 Day Price Target: $3.90 Issued 01/20/2015 By Sierra Equity

****Our Latest Publisher Pick is The Staffing Group (TSGL) ****

Many of our publisher picks rise 100%, 200% or more once they hit the front page of our blog. Get some, sit back and enjoy the ride! Recent big winners include BSTO, XCLL, GRLT, HHSE, UAPC, AEMD, XTRN, RGMI and our previous pick PPCH which ran up over 200% and counting!

With over 1 million visitors to our blog and thousands of visitors daily, Sierra World Equity Review will be giving MASSIVE MULTIPLE DAY targeted audience exposure to our latest publisher pick The Staffing Group (TSGL), with millions in revenues and net revenues up a WHOPPING 62%, operating in 3 states, only 35 Million O/S most owned by the insiders and a price target of 0.31 cents, TSGL might just be the most undervalued stock we have ever seen, trading now at historic lows! 

 

Here is why our publisher has initiated a long position in The Staffing Group (TSGL):

The Staffing Group (TSGL) generates revenues through it's subsidiary EmployUS a highly successful staffing company formed in September 2010 to respond to the relief and recovery of the major oil spill in the Gulf of Mexico.  


EmployUS, has since expanded to provide services on most major construction, chemical, and maritime projects in the Southeast United States. From its single initial project three years ago, EmployUS has grown to ten offices in three stateswith sales exceeding $15,000,000, more than 150 customers and over 3,000 people employed as of September 30, 2014

For the most recent 3 month period ending September 2014 The Staffing Group (TSGL) generated over $5 Million in net revenues ($5,187,602 to be exact) 

For the 9 month period ending September 2014 The Staffing Group (TSGL) generated almost $17 Million in net revenues ($16,715,436 to be exact) up a WHOPPING 62% for the same time frame in 2013.

From it's most recent September 2014 10Q filing The Staffing Group (TSGL) has assets of over a million dollars ($1,907,245 million to be exact)


The Staffing Group (TSGL) has a great share structure with only 35,100,011 million O/S and a float of approximately 23 million. On the latest 10Q insiders are reported to hold over 90% of the O/S meaning that the share price here could move up very quickly!!

The Staffing Group (TSGL) is current on it's SEC reporting and has audited financials. (A very healthy sign!)

ALLOTCBB has a 0.31 cent SIX month price target for The Staffing Group (TSGL), this stock is so under the radar that the potential for huge percentage gains is possible especially considering the 52 week high hit 0.59 cents AND NOW with the company revenue growth up a WHOPPING 62% (9 month period September 2014 vs 2013) the stock looks ready to bounce back. NOW is the time to buy The Staffing Group (TSGL).


Follow Sierra on Twitter To Get Our Next Publisher Pick~~Follow Sierra on Twitter

About Sierra World Equity Review

Every day we present our publisher's pick where we profile a stock that our publisher has taken a position in, we believe that the stock is extremely undervalued with potential for significant percentage gains. We also issue short term daily buy or sell ratings with 5 day price targets for stocks in all industries across all markets. 

Sierra World Equity Review and it's publisher have not been compensated to promote The Staffing Group (TSGL) but do hold a long position in the stock. We are not affiliated with any executives, owners, brokers, promoters or analysts. The publisher of Sierra World Equity Review is not a registered investment adviser, before making a purchase or sale of any securities featured on this site, we strongly recommend consultation with a registered securities representative. Please remember to do your own due diligence in regards to any stocks that appear on our websites, please read our disclaimer and privacy policy below.

Array BioPharma, Inc. (ARRY) BUY ~ 5 Day Price Target: $5.20 Issued 01/20/2015 By Sierra Equity

Array BioPharma, Inc. (ARRY) BUY ~ 5 Day Price Target: $5.20 Issued 01/20/2015 By Sierra Equity

****Our Latest Publisher Pick is Propanc Health Group Corp. (PPCH) ****

Many of our publisher picks rise 100%, 200% or more once they hit the front page of our blog. Get some, sit back and enjoy the ride! Recent big winners include BSTO, XCLL, GRLT, HHSE, UAPC, AEMD, XTRN and RGMI

With over 1 million visitors to our blog and thousands of visitors daily, Sierra World Equity Review will be giving MASSIVE MULTIPLE DAY targeted audience exposure to our latest publisher pick Propanc Health Group Corp. (PPCH). 
Currently trading in the sub-penny range Propanc Health Group Corp. (PPCH) is likely the MOST UNDERVALUED BIOTECH stock across all markets
With it's revolutionary peer reviewed cancer fighting drug PRP set for FDA regulatory process and the company actively soliciting Big Pharma in marketing efforts for potential licensing suitors, now is the time to buy shares!

Here is why our publisher has taken a long position on Propanc Health Group Corp. (PPCH)

Propanc (PPCH) is a cutting edge small biotech company based in Melbourne Australia who has developed a unique drug for the treatment of many types of cancer specifically targeting the process of metastasisCancer becomes far more serious and difficult to treat when it spreads to new locations within the body, this process is called metastasis.


What makes this new drug particularly important is that there are currently no FDA -approved drugs specifically targeting metastatic cancer, yet if metastasis could be halted most cancers would not be serious or fatal.

Propanc (PPCH) has developed a blend of naturally-occurring chemicals - PRP - that has now been shown to specifically block or reverse the processes that lead to the development of metastases and their ability to grow and spread further. These chemicals, or proenzymes, are normally manufactured by the pancreas.

Consider these exciting facts:

-In tests on cancer cells, PRP was able to halt the growth of cancer cells and cause these cells to undergo cell death.
-PRP was also able to cause malignant cancer cells to transition to more harmless cell types, no longer cancerous.
-these changes in cancer cells caused by PRP indicate that PRP may be highly effective in the treatment of metastatic cancers of many typesThe results of these studies have been published in the peer-reviewed scientific journal Cellular Oncology. 
-currently, there are no drugs approved for the targeting of metastatic cancer, placing Propanc (PPCH) in a strong position as the regulatory process moves forward.
 
- Propanc (PPCH) has filed global patent applications as well with the US Patent and Trademark Office, seeking approval of pending claims covering its novel product candidates, PRP and PRP-DCM.
-Propanc (PPCH) will be meeting with the FDA, to file for a Investigational New Drug (IND) prior to undertaking formal IND-enabling studies to support entry into Phase I human trials.

-Propanc (PPCH) has also commenced marketing efforts to potential licensing suitors, such as Big Pharma, Biotechs and Specialty Pharma Companies. These licensing partners who may be interested in licensing PRP as part of their oncology portfolio.  Such licensing deals can often fast track potential earnings and revenue for early stage companies.




Follow Sierra on Twitter To Get Our Next Publisher Pick~~Follow Sierra on Twitter

About Sierra World Equity Review

Every day we present our publisher's pick where we profile a stock that our publisher has taken a position in, we believe that the stock is extremely undervalued with potential for significant percentage gains. We also issue short term daily buy or sell ratings with 5 day price targets for stocks in all industries across all markets. 

Sierra World Equity Review and it's publisher have not been compensated to promote Propanc Health Group Corp. (PPCH) but do hold a long position in the stock. We are not affiliated with any executives, owners, brokers, promoters or analysts. The publisher of Sierra World Equity Review is not a registered investment adviser, before making a purchase or sale of any securities featured on this site, we strongly recommend consultation with a registered securities representative. Please remember to do your own due diligence in regards to any stocks that appear on our websites, please read our disclaimer and privacy policy below.

Alkermes plc (ALKS) BUY ~ 5 Day Price Target: $72.30 Issued 01/20/2015 By Sierra Equity

Alkermes plc (ALKS) BUY ~ 5 Day Price Target: $72.30 Issued 01/20/2015 By Sierra Equity

****Our Latest Publisher Pick is Propanc Health Group Corp. (PPCH) ****

Many of our publisher picks rise 100%, 200% or more once they hit the front page of our blog. Get some, sit back and enjoy the ride! Recent big winners include BSTO, XCLL, GRLT, HHSE, UAPC, AEMD, XTRN and RGMI

With over 1 million visitors to our blog and thousands of visitors daily, Sierra World Equity Review will be giving MASSIVE MULTIPLE DAY targeted audience exposure to our latest publisher pick Propanc Health Group Corp. (PPCH). 
Currently trading in the sub-penny range Propanc Health Group Corp. (PPCH) is likely the MOST UNDERVALUED BIOTECH stock across all markets
With it's revolutionary peer reviewed cancer fighting drug PRP set for FDA regulatory process and the company actively soliciting Big Pharma in marketing efforts for potential licensing suitors, now is the time to buy shares!

Here is why our publisher has taken a long position on Propanc Health Group Corp. (PPCH)

Propanc (PPCH) is a cutting edge small biotech company based in Melbourne Australia who has developed a unique drug for the treatment of many types of cancer specifically targeting the process of metastasisCancer becomes far more serious and difficult to treat when it spreads to new locations within the body, this process is called metastasis.


What makes this new drug particularly important is that there are currently no FDA -approved drugs specifically targeting metastatic cancer, yet if metastasis could be halted most cancers would not be serious or fatal.

Propanc (PPCH) has developed a blend of naturally-occurring chemicals - PRP - that has now been shown to specifically block or reverse the processes that lead to the development of metastases and their ability to grow and spread further. These chemicals, or proenzymes, are normally manufactured by the pancreas.

Consider these exciting facts:

-In tests on cancer cells, PRP was able to halt the growth of cancer cells and cause these cells to undergo cell death.
-PRP was also able to cause malignant cancer cells to transition to more harmless cell types, no longer cancerous.
-these changes in cancer cells caused by PRP indicate that PRP may be highly effective in the treatment of metastatic cancers of many typesThe results of these studies have been published in the peer-reviewed scientific journal Cellular Oncology. 
-currently, there are no drugs approved for the targeting of metastatic cancer, placing Propanc (PPCH) in a strong position as the regulatory process moves forward.
 
- Propanc (PPCH) has filed global patent applications as well with the US Patent and Trademark Office, seeking approval of pending claims covering its novel product candidates, PRP and PRP-DCM.
-Propanc (PPCH) will be meeting with the FDA, to file for a Investigational New Drug (IND) prior to undertaking formal IND-enabling studies to support entry into Phase I human trials.

-Propanc (PPCH) has also commenced marketing efforts to potential licensing suitors, such as Big Pharma, Biotechs and Specialty Pharma Companies. These licensing partners who may be interested in licensing PRP as part of their oncology portfolio.  Such licensing deals can often fast track potential earnings and revenue for early stage companies.




Follow Sierra on Twitter To Get Our Next Publisher Pick~~Follow Sierra on Twitter

About Sierra World Equity Review

Every day we present our publisher's pick where we profile a stock that our publisher has taken a position in, we believe that the stock is extremely undervalued with potential for significant percentage gains. We also issue short term daily buy or sell ratings with 5 day price targets for stocks in all industries across all markets. 

Sierra World Equity Review and it's publisher have not been compensated to promote Propanc Health Group Corp. (PPCH) but do hold a long position in the stock. We are not affiliated with any executives, owners, brokers, promoters or analysts. The publisher of Sierra World Equity Review is not a registered investment adviser, before making a purchase or sale of any securities featured on this site, we strongly recommend consultation with a registered securities representative. Please remember to do your own due diligence in regards to any stocks that appear on our websites, please read our disclaimer and privacy policy below.

Amicus Therapeutics, Inc. (FOLD) BUY ~ 5 Day Price Target: $9.20 Issued 01/20/2015 By Sierra Equity

Amicus Therapeutics, Inc. (FOLD) BUY ~ 5 Day Price Target: $9.20 Issued 01/20/2015 By Sierra Equity

****Our Latest Publisher Pick is Propanc Health Group Corp. (PPCH) ****

Many of our publisher picks rise 100%, 200% or more once they hit the front page of our blog. Get some, sit back and enjoy the ride! Recent big winners include BSTO, XCLL, GRLT, HHSE, UAPC, AEMD, XTRN and RGMI

With over 1 million visitors to our blog and thousands of visitors daily, Sierra World Equity Review will be giving MASSIVE MULTIPLE DAY targeted audience exposure to our latest publisher pick Propanc Health Group Corp. (PPCH). 
Currently trading in the sub-penny range Propanc Health Group Corp. (PPCH) is likely the MOST UNDERVALUED BIOTECH stock across all markets
With it's revolutionary peer reviewed cancer fighting drug PRP set for FDA regulatory process and the company actively soliciting Big Pharma in marketing efforts for potential licensing suitors, now is the time to buy shares!

Here is why our publisher has taken a long position on Propanc Health Group Corp. (PPCH)

Propanc (PPCH) is a cutting edge small biotech company based in Melbourne Australia who has developed a unique drug for the treatment of many types of cancer specifically targeting the process of metastasisCancer becomes far more serious and difficult to treat when it spreads to new locations within the body, this process is called metastasis.


What makes this new drug particularly important is that there are currently no FDA -approved drugs specifically targeting metastatic cancer, yet if metastasis could be halted most cancers would not be serious or fatal.

Propanc (PPCH) has developed a blend of naturally-occurring chemicals - PRP - that has now been shown to specifically block or reverse the processes that lead to the development of metastases and their ability to grow and spread further. These chemicals, or proenzymes, are normally manufactured by the pancreas.

Consider these exciting facts:

-In tests on cancer cells, PRP was able to halt the growth of cancer cells and cause these cells to undergo cell death.
-PRP was also able to cause malignant cancer cells to transition to more harmless cell types, no longer cancerous.
-these changes in cancer cells caused by PRP indicate that PRP may be highly effective in the treatment of metastatic cancers of many typesThe results of these studies have been published in the peer-reviewed scientific journal Cellular Oncology. 
-currently, there are no drugs approved for the targeting of metastatic cancer, placing Propanc (PPCH) in a strong position as the regulatory process moves forward.
 
- Propanc (PPCH) has filed global patent applications as well with the US Patent and Trademark Office, seeking approval of pending claims covering its novel product candidates, PRP and PRP-DCM.
-Propanc (PPCH) will be meeting with the FDA, to file for a Investigational New Drug (IND) prior to undertaking formal IND-enabling studies to support entry into Phase I human trials.

-Propanc (PPCH) has also commenced marketing efforts to potential licensing suitors, such as Big Pharma, Biotechs and Specialty Pharma Companies. These licensing partners who may be interested in licensing PRP as part of their oncology portfolio.  Such licensing deals can often fast track potential earnings and revenue for early stage companies.




Follow Sierra on Twitter To Get Our Next Publisher Pick~~Follow Sierra on Twitter

About Sierra World Equity Review

Every day we present our publisher's pick where we profile a stock that our publisher has taken a position in, we believe that the stock is extremely undervalued with potential for significant percentage gains. We also issue short term daily buy or sell ratings with 5 day price targets for stocks in all industries across all markets. 

Sierra World Equity Review and it's publisher have not been compensated to promote Propanc Health Group Corp. (PPCH) but do hold a long position in the stock. We are not affiliated with any executives, owners, brokers, promoters or analysts. The publisher of Sierra World Equity Review is not a registered investment adviser, before making a purchase or sale of any securities featured on this site, we strongly recommend consultation with a registered securities representative. Please remember to do your own due diligence in regards to any stocks that appear on our websites, please read our disclaimer and privacy policy below.